تقرير
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
| العنوان: | The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease |
|---|---|
| المؤلفون: | University College Dublin |
| المساهمون: | Karl Neff, Clinical Research Fellow |
| المصدر: | Fenske WK, Dubb S, Bueter M, Seyfrd F, Patel K, Tam FW, Frankel AH, le Roux CW. Effect of bartr surgery-duced weht loss on renal and system flammatn and blood pressure: a 12-month prospecte study. Surg Obes Relat D. 2013 Jul-Aug;9(4):559-68. do 10.1016/j.soard.2012.03.009. Epub 2012 Apr 10. Mas AD, Chuah LL, Lascaratos G, Faruq S, Mohe AA, Shah PR, Gl M, Jackson SN, Johnston DG, Olbers T, le Roux CW. Bartr surgery does not exacerbate and may be benefl for the mrovascular complatns of type 2 dbetes. Dbetes Care. 2012 Dec;35(12):e81. do 10.2337/dc11-2353. No abstract avaable. Megu El Nahas A, Bello AK. Chron kney dease: the global challenge. Lancet. 2005 Jan 22-28;365(9456):331-40. do 10.1016/S0140-6736(05)17789-7. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garc-Perez J. flammatory molecules and pathways the pathogenes of dbet nephropathy. Nat Rev Nephrol. 2011 Jun;7(6):327-40. do 10.1038/nrneph.2011.51. Epub 2011 May 3. L AK, Tesch GH. flammatn dbet nephropathy. Medtors flamm. 2012;2012:146154. do 10.1155/2012/146154. Epub 2012 Aug 21. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snah A. Glucagon-le pepte analogues for type 2 dbetes mellus. Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD006423. do 10.1002/14651858.CD006423.pub2. Hogan AE, Tob AM, Ahern T, Corran MA, Gaoatswe G, Jackson R, O'Rely V, Lynch L, Doherty DG, Moynagh PN, Kby B, O'Connell J, O'Shea D. Glucagon-le pepte-1 (GLP-1) and the regulatn of human varnt natural kler T cells: lessons from obesy, dbetes and psors. Dbetolog. 2011 Nov;54(11):2745-54. do 10.1007/s00125-011-2232-3. Epub 2011 Jul 9. Lynch LA, O'Connell JM, Kwasn AK, Cawood TJ, O'Farrelly C, O'Shea DB. Are natural kler cells protectg the metabolally healthy obese patnt? Obesy (Sver Sprg). 2009 Mar;17(3):601-5. do 10.1038/oby.2008.565. Epub 2008 Dec 18. Lynch L, O'Shea D, Wter DC, Geoghegan J, Doherty DG, O'Farrelly C. varnt NKT cells and CD1d(+) cells amass human omentum and are depleted patnts wh cancer and obesy. Eur J munol. 2009 Jul;39(7):1893-901. do 10.1002/ej200939349. Chow FY, Nol-Paterson DJ, Ozols E, Atks RC, Roll BJ, Tesch GH. Monocyte chemoattractant prote-1 promotes the development of dbet renal jury streptozotoc-treated me. Kney t. 2006 Jan;69(1):73-80. do 10.1038/sj.k5000014. Chow F, Ozols E, Nol-Paterson DJ, Atks RC, Tesch GH. Macrophages mouse type 2 dbet nephropathy: correlatn wh dbet state and progresse renal jury. Kney t. 2004 Jan;65(1):116-28. do 10.1111/j.1523-1755.2004.00367.x. KanamorH, Matsubara T, Ma A, SumE, NagaK, TakahashT, Abe H, hara N, Fukatsu A, Okamoto H, Ka T, DoT, AraH. hn of MCP-1/CCR2 pathway amelrates the development of dbet nephropathy. Bchem Bphys Res Commun. 2007 Sep 7;360(4):772-7. do 10.1016/j.bbrc.2007.06.148. Epub 2007 Jul 6. Tarabra E, GntS, Barutta F, Salv G, Burt D, DeferrarG, Gambo R, Vergola D, Pach S, Per PC, CamussG, Gruden G. Effect of the monocyte chemoattractant prote-1/CC chemoke receptor 2 system on nephr expressn streptozotoc-treated me and human cultured podocytes. Dbetes. 2009 Sep;58(9):2109-18. do 10.2337/db08-0895. Epub 2009 Jul 8. Navarro JF, Mena FJ, Mora C, Leon C, Garc J. Renal pro-flammatory cytoke gene expressn dbet nephropathy: effect of angtens-convertg enzyme hn and pentoxylle admtratn. Am J Nephrol. 2006;26(6):562-70. do 10.1159/000098004. Epub 2006 Dec 13. YozaK, Shata K, SasakM, Tone A, Ohga S, UsuH, Okada S, Wada J, Nagase R, Ogawa D, Shata Y, Mako H. Methotrexate prevents renal jury experental dbet rats v antflammatory actns. J Am Soc Nephrol. 2005 Nov;16(11):3326-38. do 10.1681/ASN.2004111011. Epub 2005 Sep 21. Tone A, Shata K, SasakM, Ohga S, YozaK, Nhha S, UsuH, Nagase R, Ogawa D, Okada S, Shata Y, Wada J, Mako H. Erythromyc amelrates renal jury v antflammatory effects experental dbet rats. Dbetolog. 2005 Nov;48(11):2402-11. do 10.1007/s00125-005-1945-6. Epub 2005 Oct 18. Blando-Rosano M, Perez-Arana G, Mellado-G JM, Segundo C, Aguar-Dsdado M. Antprolerate effect of pro-flammatory cytokes cultured beta cells assocted wh extracellular snal-regulated kase 1/2 pathway hn: protecte role of glucagon-le pepte -1. J Mol Endocrol. 2008 Jul;41(1):35-44. do 10.1677/JME-07-0154. Epub 2008 May 16. Kodera R, Shata K, Kataoka HU, Takatsuka T, Mamoto S, SasakM, KajanN, Nhha S, SaraK, Hota D, Sato C, Ogawa D, Mako H. Glucagon-le pepte-1 receptor agont amelrates renal jury through s antflammatory actn whout lowerg blood glucose level a rat model of type 1 dbetes. Dbetolog. 2011 Apr;54(4):965-78. do 10.1007/s00125-010-2028-x. Epub 2011 Jan 21. Ahern T, Tob AM, Corran M, Hogan A, Sweeney C, Kby B, O'Shea D. Glucagon-le pepte-1 analogue therapy for psors patnts wh obesy and type 2 dbetes: a prospecte cohort study. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1440-3. do 10.1111/j.1468-3083.2012.04609.x. Epub 2012 Jun 13. HattorS. Saglt reduces albumur patnts wh type 2 dbetes. Endocr J. 2011;58(1):69-73. do 10.1507/endocrj.k10e-382. Epub 2010 Dec 28. Cummgs BP, Stanhope KL, Graham JL, Bask DG, Grfen SC, Nsson C, Sams A, Knudsen LB, Raun K, Havel PJ. Chron admtratn of the glucagon-le pepte-1 analog, laglute, delays the onset of dbetes and lowers trlyceres UCD-T2DM rats. Dbetes. 2010 Oct;59(10):2653-61. do 10.2337/db09-1564. Epub 2010 Jul 9. zucchSE, Bergenstal RM, Buse JB, Dmant M, FerrannE, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; Ameran Dbetes Assoctn (ADA); European Assoctn for the Study of Dbetes (EASD). Management of hyperglycem type 2 dbetes: a patnt-centered approach: posn statement of the Ameran Dbetes Assoctn (ADA) and the European Assoctn for the Study of Dbetes (EASD). Dbetes Care. 2012 Jun;35(6):1364-79. do 10.2337/dc12-0413. Epub 2012 Apr 19. No abstract avaable. Erratum : Dbetes Care. 2013 Feb;36(2):490. Pkney J, Fox T, Ranganath L. Selectg GLP-1 agonts the management of type 2 dbetes: dferentl pharmacology and therapeut benefs of laglute and exenate. Ther Cl Rk Manag. 2010 Sep 7;6:401-11. do 10.2147/tcrm.s7313. Jacobsen LV, Hdsberger C, Robson R, Zdravkov M. Effect of renal pament on the pharmacokets of the GLP-1 analogue laglute. Br J Cl Pharmacol. 2009 Dec;68(6):898-905. do 10.1111/j.1365-2125.2009.03536.x. Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease |
| الوصول الحر: | https://clinicaltrials.gov/ct2/show/NCT01847313Test |
| قاعدة البيانات: | ClinicalTrials.gov |
| الوصف غير متاح. |